Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours
NCT07563738Phase 2Recruiting
- Sponsor
- Orion Corporation
- Start
- Mar 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of ODM-212 in mesothelioma, pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Orion Corporation. Primary endpoint: Incidence of Dose Limiting Toxicities and Adverse Events at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
ODM-212
03
Conditions
mesotheliomapancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07563738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563738.